Literature DB >> 2860126

Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

M L Vance, D L Kaiser, W S Evans, R Furlanetto, W Vale, J Rivier, M O Thorner.   

Abstract

Growth hormone (GH) secretory patterns were studied in a patient with ectopic growth hormone releasing factor (GRF) secretion and in normal men given continuous infusions of human growth hormone releasing factor (1-40)-OH (hGRF-40). In the patient with ectopic GRF secretion, GH secretion was pulsatile despite continuously elevated immunoreactive GRF levels. To determine if pulsatile GH secretion is maintained in normal subjects, we administered to six healthy young men vehicle or hGRF-40, 2 ng/kg per min, for 24 h and gave a supramaximal intravenous bolus dose of hGRF-40, 3.3 micrograms/kg, after 23.5 h of infusion. hGRF-40 infusion resulted in greater GH secretion than did vehicle infusion and pulsatile GH secretion was maintained throughout hGRF-40 infusion. During the 23.5 h of vehicle infusion, total GH secretion (microgram; mean +/- SEM) was 634 +/- 151 compared with 1,576 +/- 284 during hGRF-40 infusion (P = 0.042). The GH response to the intravenous bolus of hGRF-40 was greater after vehicle infusion than after hGRF-40 infusion; 877 +/- 170 and 386 +/- 125 micrograms of GH was secreted after the bolus on vehicle and hGRF-40 days, respectively (P = 0.015). The total amount of GH secreted during the 25.5 h of the two study days was not different; 1,504 +/- 260 and 1,952 +/- 383 micrograms were secreted during vehicle and hGRF-40 days, respectively (P = 0.36). Not only was pulsatile GH secretion maintained during hGRF-40 infusion, but there was augmentation of naturally occurring GH pulses, which is in contrast to the effect of gonadotropin-releasing hormone on gonadotropin secretion. We suggest that GH pulses are a result of GRF secretion that is associated with a diminution or withdrawal of somatostatin secretion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860126      PMCID: PMC425499          DOI: 10.1172/JCI111864

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  Metabolic clearance and production rates of human growth hormone in subjects with normal and abnormal growth.

Authors:  M H MacGillivray; L A Frohman; J Doe
Journal:  J Clin Endocrinol Metab       Date:  1970-05       Impact factor: 5.958

3.  Gonadotropin-releasing hormone modulation of its own pituitary receptors: evidence for biphasic regulation.

Authors:  R N Clayton
Journal:  Endocrinology       Date:  1982-07       Impact factor: 4.736

4.  Pituitary-ovarian axis responsivity to prolonged gonadotropin-releasing hormone infusion in normal and hyperprolactinemic women.

Authors:  J F Caro; P D Woolf
Journal:  J Clin Endocrinol Metab       Date:  1980-06       Impact factor: 5.958

5.  Induction of immunoreactive somatomedin C human serum by growth hormone: dose-response relationships and effect on chromatographic profiles.

Authors:  K C Copeland; L E Underwood; J J Van Wyk
Journal:  J Clin Endocrinol Metab       Date:  1980-04       Impact factor: 5.958

6.  Growth hormone stimulates hypothalamic somatostatin.

Authors:  Y C Patel
Journal:  Life Sci       Date:  1979-04-23       Impact factor: 5.037

7.  Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution.

Authors:  M Berelowitz; S L Firestone; L A Frohman
Journal:  Endocrinology       Date:  1981-09       Impact factor: 4.736

8.  Pitfalls in the somatomedin-C radioimmunoassay.

Authors:  R W Furlanetto
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

9.  Evidence for autoregulation of growth hormone secretion via the central nervous system.

Authors:  G S Tannenbaum
Journal:  Endocrinology       Date:  1980-12       Impact factor: 4.736

10.  Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.

Authors:  M L Vance; D L Kaiser; W S Evans; M O Thorner; R Furlanetto; J Rivier; W Vale; G Perisutti; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

View more
  19 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Authors:  Hideo Makimura; Meghan N Feldpausch; Alison M Rope; Linda C Hemphill; Martin Torriani; Hang Lee; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2012-09-26       Impact factor: 5.958

4.  Acute effects of heated resistance exercise in female and male power athletes.

Authors:  Julia R Casadio; Adam G Storey; Fabrice Merien; Andrew E Kilding; James D Cotter; Paul B Laursen
Journal:  Eur J Appl Physiol       Date:  2017-07-26       Impact factor: 3.078

Review 5.  The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses.

Authors:  M L Vance
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

Review 6.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

Review 7.  Ectopic secretion of growth hormone-releasing hormone in man.

Authors:  M Losa; J Schopohl; K von Werder
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

8.  Relationship between hypophyseal portal GHRH and somatostatin and peripheral GH levels in the conscious sheep.

Authors:  M Cataldi; E Magnan; V Guillaume; A Dutour; B Conte-Devolx; G Lombardi; C Oliver
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

9.  Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.

Authors:  C A Jaffe; R D Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Evidence for acyl-ghrelin modulation of growth hormone release in the fed state.

Authors:  Ralf Nass; Leon S Farhy; Jianhua Liu; Catherine E Prudom; Michael L Johnson; Paula Veldhuis; Suzan S Pezzoli; Mary Clancy Oliveri; Bruce D Gaylinn; H Mario Geysen; Michael O Thorner
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.